Population profile of patients who started neoadjuvant therapy for breast neoplasia at Hospital Universitário São Francisco de Assis, Bragança Paulista, in the period from 2020 to 2021

Abstract

Background: Breast cancer is the second most prevalent tumor in female patients, excluding non-melanoma skin tumors. Screening, early diagnosis and institution of appropriate therapy are essential for the best therapeutic outcome for this population. Aim: To evaluate the population profile of patients who started neoadjuvant therapy for breast cancer in our Service.

Method: Data were collected from the medical records of patients registered at the São Francisco de Assis University Hospital in Providência de Deus, Bragança Paulista – SP, Brazil, who underwent neoadjuvant chemotherapy treatment at the oncology outpatient clinic, in 2020 and 2021. The variables collected from the medical records were age, weight, and height for calculating body mass index (BMI), estrogen and progesterone values, and chemotherapy duration. Data regarding menopause, histological type and grade, Her II status, chemotherapy regimens, type of surgery, axillary dissection, biopsies characteristics and pathological response were also collected.

Results: The T3N0M0 staging, the presence of a ductal carcinoma, and the presence of a low histological differentiation were significant when compared to the other classifications within their respective groups. Furthermore, the proportions related to the score 0 of the Her II status and the type of ACT chemotherapy were also statistically significant.

Conclusion: The patients evaluated in our Service. With an average age of 50 years, they present a profile similar to other analyzes carried out in Brazil.